First Amendment to License Agreement
Exhibit 10.2
First Amendment to License Agreement
The License Agreement effective as of December 31, 2015, between
|
A. |
Vixen Pharmaceuticals, a Delaware corporation, as assigned to and assumed by Aclaris Therapeutics Inc., having offices at 000 Xxx Xxxx, Xxxxx 000, Xxxxx, Xxxxxxxxxxxx 00000 (“RECIPIENT”) pursuant to the Stock Purchase Agreement signed by Vixen Pharmaceuticals and Aclaris Therapeutics Inc., dated March 24, 2015; and |
|
B. |
The Trustees of Columbia University in the City of New York, having an address at c/o Columbia Technology Ventures, 00 Xxxxxxxxx Xxxxxx, Xxxxx 0X, Xxx Xxxx, Xxx Xxxx 00000 (“Columbia”), |
a copy of the License Agreement is attached herewith as Schedule A (the “Agreement”), is hereby amended as follows:
|
1. |
Please amend Exhibit A by adding the following Section: |
|
IR |
Docket |
Patent/Application Title |
Patent/Application No. |
Filing Date |
Status |
|
[***] |
[***] |
[***] |
[***] |
[***] |
[***] |
|
2. |
This Amendment is effective as of June 27, 2018. |
|
3. |
All other terms and conditions of the Agreement shall remain in full force and effect, except as expressly amended herein. If there is any inconsistency or conflict between this Amendment and the Agreement, the provisions of this Amendment shall govern and control. This Amendment shall be binding upon, and shall inure to the benefit of, the parties hereto and their respective successors and assigns. |
AGREED:
|
Recipient |
|
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK |
|
|
/s/ Xxxx Xxxxxx |
|
/s/ Xxxx X. Xxxxxxxx |
|
|
Printed Name: Xxxx Xxxxxx |
|
Printed Name: Xxxx X. Xxxxxxxx |
|
|
Title: President and CEO |
|
Title: AVP for CTV at Columbia |
|
|
Date:6/27/18 |
|
Date: 6/28/2018 |
|
|
|
|
TT 52520 |
|
Attachments:Schedule A – the Agreement
Page 1 of 1
Confidential and Proprietary
CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
